. home.aspx

NEWS

home.aspx
   


Teva’s migraine drug hits key PhIII goal

June 01, 2017 / Selina McKee
SHARESHARESHARE

Patients treated with both monthly and quarterly dosing regimens of the drug experienced a statistically significant reduction in the number of monthly headache days of at least moderate severity versus placebo during the 12 week period after first dose.